AR115722A1 - Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos - Google Patents

Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos

Info

Publication number
AR115722A1
AR115722A1 ARP190101933A ARP190101933A AR115722A1 AR 115722 A1 AR115722 A1 AR 115722A1 AR P190101933 A ARP190101933 A AR P190101933A AR P190101933 A ARP190101933 A AR P190101933A AR 115722 A1 AR115722 A1 AR 115722A1
Authority
AR
Argentina
Prior art keywords
peripheral neuropathies
preventing
treating
rgma
agent
Prior art date
Application number
ARP190101933A
Other languages
English (en)
Inventor
Atsushi Sasaki
Joseph M Palumbo
Hirokazu Ishida
Hayato Ishida
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR115722A1 publication Critical patent/AR115722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente provee métodos para prevenir o tratar neuropatías periféricas y para prevenir o tratar síntomas de dolor asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos, y también provee un agente para prevenir o tratar neuropatías periféricas o síntomas de dolor asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos, en donde el agente contiene una sustancia inhibidora de RGM. Reivindicación 1: Un agente para prevenir o tratar una neuropatía periférica, caracterizado porque el agente comprende una sustancia inhibidora de RGM. Reivindicación 2: El agente de acuerdo a la reivindicación 1, caracterizado porque la sustancia inhibidora de RGM es una sustancia inhibidora de RGMa. Reivindicación 3: El agente de acuerdo a la reivindicación 2, caracterizado porque la sustancia inhibidora de RGMa es un anticuerpo neutralizante anti-RGMa o un fragmento del mismo. Reivindicación 4: El agente de acuerdo a la reivindicación 3, caracterizado porque el anticuerpo neutralizante anti-RGMa es un anticuerpo humanizado. Reivindicación 15: Un método para prevenir o tratar una neuropatía periférica, caracterizado porque comprende administrar una cantidad eficaz de una sustancia inhibidora anti-RGMa a un mamífero que lo necesite.
ARP190101933A 2018-07-10 2019-07-10 Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos AR115722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862696052P 2018-07-10 2018-07-10

Publications (1)

Publication Number Publication Date
AR115722A1 true AR115722A1 (es) 2021-02-17

Family

ID=69142006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101933A AR115722A1 (es) 2018-07-10 2019-07-10 Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos

Country Status (15)

Country Link
US (1) US20210269516A1 (es)
EP (1) EP3821908A4 (es)
JP (2) JP7449859B2 (es)
KR (1) KR20210032412A (es)
CN (4) CN112533635A (es)
AR (1) AR115722A1 (es)
AU (2) AU2019301336B2 (es)
BR (1) BR112021000300A2 (es)
CA (1) CA3106074A1 (es)
IL (1) IL280018A (es)
MX (1) MX2021000324A (es)
PH (1) PH12021550055A1 (es)
SG (1) SG11202100235YA (es)
TW (1) TW202019481A (es)
WO (1) WO2020013238A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091632A4 (en) * 2020-01-15 2024-07-10 Univ Osaka AGENT FOR THE PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1355666B1 (en) * 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
AU2005221471A1 (en) 2004-03-11 2005-09-22 Bioclues, Inc Axon regeneration promoter
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
CN104487455A (zh) * 2012-01-27 2015-04-01 艾伯维德国有限责任两合公司 用于诊断和治疗与神经突变性相关的疾病的组合物和方法
JP6497760B2 (ja) 2015-04-28 2019-04-10 田辺三菱製薬株式会社 ＲＧＭａ結合タンパク質及びその使用
CN109496218A (zh) * 2016-06-01 2019-03-19 艾伯维公司 用于治疗脊髓损伤和疼痛的抗反义导向分子a（rgma）拮抗性抗体

Also Published As

Publication number Publication date
US20210269516A1 (en) 2021-09-02
MX2021000324A (es) 2021-03-25
AU2023200728A1 (en) 2023-03-16
CN117919418A (zh) 2024-04-26
CN117919420A (zh) 2024-04-26
WO2020013238A1 (ja) 2020-01-16
EP3821908A4 (en) 2022-03-30
BR112021000300A2 (pt) 2021-04-06
CN117919419A (zh) 2024-04-26
AU2019301336A1 (en) 2021-02-11
TW202019481A (zh) 2020-06-01
CA3106074A1 (en) 2020-01-16
PH12021550055A1 (en) 2021-11-08
CN112533635A (zh) 2021-03-19
SG11202100235YA (en) 2021-02-25
EP3821908A1 (en) 2021-05-19
JP7449859B2 (ja) 2024-03-14
IL280018A (en) 2021-03-01
JPWO2020013238A1 (ja) 2021-07-15
KR20210032412A (ko) 2021-03-24
AU2019301336B2 (en) 2022-11-24
JP2024026683A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
MD3455259T2 (ro) Combinație de anticorpi anti-PD-1 și radiație pentru tratarea cancerului
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
AR115722A1 (es) Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos
CL2020000974A1 (es) Tratamiento de la glomerulosclerosis focal y segmentaria con anatagonistas ccr2.
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
AR107983A1 (es) Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2022000214A1 (es) Inhibidores de enzimas
CL2020003171A1 (es) Dosis y efecto de un antagonista de c5a con una vasculitis asociada a anca.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
BR112022018161A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
EA202191423A1 (ru) Безопасный и эффективный способ лечения псориаза специфичным к ил-23 антителом
AR122984A1 (es) Métodos y combinaciones de inhibidor de kat6 para el tratamiento del cáncer